表皮生长因子受体酪氨酸激酶抑制剂在EGFR突变非小细胞肺癌中相关的心血管不良事件:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入89项随机对照试验共29813例EGFR突变非小细胞肺癌患者,评估EGFR酪氨酸激酶抑制剂的心血管不良事件风险。与安慰剂相比,第一代(OR 1.51,95%CI 1.01-2.26;高确定性;合并发生率3.2%)和第三代(OR 2.18,95%CI 1.46-3.27;高确定性;9.5%)抑制剂均与心脏不良事件风险增加相关。第三代抑制剂较第一代与更高的任何级别和≥3级心血管不良事件风险相关。
要点
- 与安慰剂相比,第一代和第三代EGFR酪氨酸激酶抑制剂均与心脏不良事件风险增加相关。
- 第三代抑制剂中奥希替尼(OR 2.53,95%CI 1.53-4.19;高确定性;8.9%)与心脏不良事件相关。
- 第三代抑制剂与心律失常风险显著更高相关(OR 3.26,95%CI 1.83-5.81;高确定性;7.3%)。
核心结论
- 在EGFR突变非小细胞肺癌患者中,第一代和第三代EGFR酪氨酸激酶抑制剂以及联合抗血管生成治疗均与心血管不良事件风险增加相关。
- 第三代抑制剂较第一代与显著更高的任何级别和≥3级心血管不良事件风险相关。
研究设计与样本
- 系统评价与网状Meta分析,检索PubMed、Embase、Web of Science、Scopus、Cochrane对照试验中心注册库及三个临床试验注册平台,检索时间从建库至2024年11月20日。
- 纳入比较EGFR酪氨酸激酶抑制剂单药与安慰剂或其他治疗的随机对照试验,共89项随机对照试验、29813例参与者,平均随访2.18年。
- 采用频率学派随机效应网状Meta分析比较不同治疗的不良药物反应,使用CINeMA方法评估证据确定性,并进行配对Meta分析比较三代EGFR酪氨酸激酶抑制剂。
主要发现
- 与安慰剂相比,第一代EGFR酪氨酸激酶抑制剂与心脏不良事件风险增加相关(OR 1.51,95%CI 1.01-2.26;高确定性;合并发生率3.2%),第三代抑制剂亦相关(OR 2.18,95%CI 1.46-3.27;高确定性;9.5%)。
- 第三代抑制剂中,奥希替尼(OR 2.53,95%CI 1.53-4.19;高确定性;8.9%)和拉泽替尼(OR 2.84,95%CI 1.17-6.91;中等确定性;2.7%)与心脏不良事件相关。
- 联合治疗如抗血管生成联合厄洛替尼或吉非替尼与血管不良事件相关(高确定性),抗血管生成联合奥希替尼与心血管不良事件相关(中等至高等确定性)。
- 第三代抑制剂与心律失常风险显著更高相关(OR 3.26,95%CI 1.83-5.81;高确定性;7.3%),包括奥希替尼单药(OR 3.35,95%CI 1.75-6.40;高确定性;6.2%)及联合抗血管生成治疗;阿美替尼与血管毒性相关。
- 配对Meta分析中,第三代抑制剂较第一代抑制剂与更高的任何级别和≥3级心血管不良事件风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk of cardiovascular adverse events associated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer (NSCLC). DESIGN: Systematic review and network meta-analysis. DATA SOURCES: PubMed, Embase, Web of Science, Scopus, Cochrane Central Register of Controlled Trials, and three clinical trial registries, from inception to 20 November 2024. STUDY SELECTION: Randomised controlled trials comparing EGFR tyrosine kinase inhibitor monotherapy with placebo or other treatments in patients with EGFR-mutated NSCLC. DATA EXTRACTION AND SYNTHESIS: Pairs of reviewers extracted data and assessed risk of bias. A random effects network meta-analysis using a frequentist approach compared adverse drug reactions across different treatments. Certainty of evidence was evaluated using the confidence in network meta-analysis approach. Pairwise meta-analyses were done to compare the three generations of EGFR tyrosine kinase inhibitors. RESULTS: The network meta-analysis comprised 89 randomised controlled trials involving 29 813 participants, mean follow-up 2.18 years. Compared with placebo, both first generation (odds ratio 1.51, 95% confidence interval 1.01 to 2.26; high certainty; pooled incidence 3.2%) and third generation EGFR tyrosine kinase inhibitors (2.18, 1.46 to 3.27; high certainty; 9.5%) were associated with increased risks of cardiac adverse events. Among third generation inhibitors, osimertinib (2.53, 1.53 to 4.19; high certainty; 8.9%) and lazertinib (2.84, 1.17 to 6.91; moderate certainty; 2.7%) were associated with cardiac adverse events. Combined therapies, such as antiangiogenesis with erlotinib or gefitinib, were associated with vascular adverse events (high certainty), whereas antiangiogenesis with osimertinib was associated with cardiovascular adverse events (moderate to high certainty). Also, the risk of arrhythmias was significantly higher with third generation inhibitors (3.26, 1.83 to 5.81; high certainty; 7.3%), such as osimertinib alone (3.35, 1.75 to 6.40; high certainty; 6.2%) and in combination with antiangiogenesis. Almonertinib was associated with vascular toxicity. In pairwise meta-analysis, third generation inhibitors were associated with higher risks of any grade and grade ≥3 cardiovascular adverse events compared with first generation inhibitors. CONCLUSIONS: In patients with EGFR-mutated NSCLC, first and third generation EGFR tyrosine kinase inhibitors, as well as combination therapies with antiangiogenesis, were associated with increased risks of cardiovascular adverse events. Risks were significantly higher with third generation compared with first generation inhibitors. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023433003.
引用
- Ma Z, Cao F, Liao M, et al. Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2025. PMID: 40897431. doi:10.1136/bmj-2024-082834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。